GLP-2 TRZ 20mg

Description

GC-2 TRZ (Tirzepatide) 20mg: Research-Grade Product Description

Key Points:

• Research suggests that Tirzepatide operates as a first-in-class, imbalanced dual GIP/GLP-1 receptor agonist, favoring GIPR activity over GLP-1R.
• Evidence indicates that unique structural modifications—including Aib substitutions and a C20 fatty diacid moiety—substantially enhance its metabolic stability and pharmacokinetic profile.
• It seems likely that its biased agonism at the GLP-1R promotes cAMP generation while limiting β-arrestin recruitment, thereby altering receptor internalization dynamics.
• Signal transduction primarily relies on the synergistic actions of the cAMP/PKA and Epac2 pathways to modulate intracellular calcium and cellular responses.
• Strictly for Research Use Only (RUO). Not for human, diagnostic, or veterinary use.

Tirzepatide, widely referenced in preclinical literature under the developmental code LY3298176, is a highly engineered 39-amino acid linear synthetic peptide. Originally conceptualized as a “twincretin,” it combines the pharmacological actions of both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) into a single molecular entity. Current research leans toward the utility of such polyagonists in elucidating complex metabolic pathways, making this peptide an essential reagent for investigating glucose homeostasis, beta-cell function, and energy expenditure in preclinical laboratory models.

Product Specifications

Product Name	GLP-2 TRZ (Tirzepatide)
Synonyms	LY3298176, Twincretin
CAS Number	2023788-19-2
Molecular Weight	~4810 Da (Calculated: 4810.52 Da)
Sequence Base	39-amino acid modified GIP backbone
Formulation	20mg Lyophilized Powder
Purity	≥98% (by HPLC and MS)
Intended Use	Research Use Only (RUO)

Structural Characteristics

The molecular architecture of Tirzepatide is fundamentally based on the native human GIP amino acid sequence, comprising a 39-amino acid backbone. To confer resistance against rapid proteolytic degradation by dipeptidyl peptidase-4 (DPP-4), the sequence features critical non-coded α-amino isobutyric acid (Aib) substitutions at positions 2 and 13. Furthermore, to facilitate prolonged half-life and enable strong albumin binding during in vivo assays, the peptide is covalently linked to a C20 fatty diacid moiety (eicosanedioic acid). This lipid chain is attached to the Lys20 residue via a hydrophilic spacer composed of γ-glutamate and two 8-amino-3,6-dioxaoctanoic acid (AEEA) linkers. The C-terminus of the peptide is amidated for structural stability.

Receptor Binding and Mechanism of Action

Tirzepatide functions as an imbalanced and biased dual receptor agonist. In in vitro pharmacological profiling, it demonstrates high-affinity binding to the GIP receptor (GIPR) with a K_i of 0.135 nM, matching the potency of native GIP. Conversely, its binding affinity for the GLP-1 receptor (GLP-1R) is approximately five-fold weaker than that of native GLP-1 (K_i = 4.23 nM).

This dual engagement leads to distinct intracellular signaling cascades. At the GIPR, the compound acts as a full agonist stimulating both cAMP generation and standard β-arrestin pathways. At the GLP-1R, however, it exhibits biased agonism, heavily favoring cyclic adenosine monophosphate (cAMP) generation over β-arrestin recruitment. Research suggests this pathway bias limits GLP-1R internalization, thereby preventing rapid receptor desensitization and promoting sustained cellular signaling.

Downstream signal transduction is strictly dependent on the elevation of intracellular cAMP, which sequentially activates Protein Kinase A (PKA) and the Exchange Protein directly Activated by cAMP 2 (Epac2). The activation of PKA induces the closure of ATP-sensitive potassium (K_ATP) channels, resulting in cellular membrane depolarization and the subsequent opening of voltage-dependent calcium channels (VDCC). Concurrently, Epac2 activation mobilizes calcium release from the endoplasmic reticulum. Together, these convergent pathways significantly increase intracellular calcium concentrations, synergistically driving the exocytosis of insulin-containing secretory granules in pancreatic β-cell models.

Research Applications

As a highly specialized biochemical reagent, GLP-2 TRZ (Tirzepatide) 20mg is utilized exclusively for in vitro and experimental animal model investigations. Principal areas of application include:

• Glucose Homeostasis: Investigating dual incretin mechanisms in pancreatic β-cell function, insulin secretion assays, and islet survival studies.
• Receptor Pharmacology: Studying biased GPCR agonism, signalosome nanodomains, and the differential roles of β-arrestin in receptor internalization and trafficking.
• Metabolic Studies: Evaluating energy expenditure, lipid metabolism, ectopic fat accumulation, and hypothalamic appetite regulation in diet-induced obesity (DIO) murine models.

Storage, Handling, and Purity

This product is supplied as a sterile-filtered, lyophilized powder. For optimal stability, it should be stored desiccated at -20°C or below. Upon reconstitution in a suitable buffer (e.g., sterile water, PBS, or appropriate assay buffer), aliquots should be prepared to avoid repeated freeze-thaw cycles and stored at -80°C. The compound meets rigorous quality control standards, with a guaranteed purity of ≥98% as determined by HPLC and Mass Spectrometry. Disclaimer: For Research Use Only (RUO). Not for human or veterinary clinical application.

Selected PubMed Citations

• Willard FS, et al. “Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist.” JCI Insight. 2020 Sep 3;5(17):e140532. PMID: 32730231.
• Coskun T, et al. “LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept.” Mol Metab. 2018 Dec;18:3-14. PMID: 30473097.
• Nauck MA, D’Alessio DA. “Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction.” Cardiovasc Diabetol. 2022 Sep 1;21(1):169. PMID: 36050763.

Sources:

1. [mdpi.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHnOHlCJUttTlr7jrmLVWtxGOdnd-SM5bbU1xguBzh66aveTY8hUy5gUDGeDb2Tbeo-Eox7ceW2AmofafTq3vXEOuVOlb6J0fWK0Vs9Ex1W2vZQePmBaPkayDLrUxOneQ==)

2. [nih.gov](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHRcUv1IQklJyQ571Y8J6KcFGMCdMiErPfhP8o4JrSpki_7ljmR4x1FAwDGhJLeNoF1_UhQH4M7kvOEX4kEro0bT8d37AnyYgscioQD6bGYg3uU2JW3QnXj9yw2UEgaPMyvKbrHg1-T)

3. [nih.gov](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFO_IQUUx_KKum8-lr5sp4LAa8I5X_mYhgJYjOPTgwAooYezy71A8jmE2VyKayOEKbrLH10BKfu0OnOzp5uPi_xYi4wBrUfSD0T3MWAPSNOFjeA9DX0lMRoinZzULpBzA==)

4. [nih.gov](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGxg7yzLzsP61PZV77H2R_zgLRxZ93StcQfotkR6uhr13wEJqGYCaLws3iR7yV5jXZu-AGXqXMkpDCXfqYpwu0TEvP1R1JkPSdp7JU-HjFQqrn8L1bGAte1nW7YdR-wfmJeJDZytFxJ)

5. [probechem.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFrmf8Mopn9UJW0KpUGZQhNsIfqWbpew2bIzvoJpcTfoZGjUyIix7zZdzv8TWkQaN_zh1O_ybPuZm8kGHDc9CbdPBmJeYaPmMSknBJ4reo4VRwrSlxQWPK27pfICiz28taYHHxD955ljUI=)

6. [rcsb.org](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEubjYW3Fr55E0hh8ClHg7gki0R6m_Bw3-1M6cmzEfQgyPEAONDXQcJMPoNOo2Pzn_SfHelSMKqm-Zqr4Ml-W1DaXDpZapdK7TcLrVejkQUgDwXuBUspBL9aJ5bqmQKY3Bw991f6yNxdt8nQbP6obDgyVCiDCvpmusVhoaUDBKIxS8QkbRhFgru37FhTtlHFEtRPWDNHtS3XT5E)

7. [seekpeptides.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEsHAF-Po6W0v437etnvN1dFebMIaKZs1bL0IwBoTAtW2Q6_DPLpsQGZyluNTddrWcDG6kmwoT7xtCEXiOzRQBSkH49TbNIp_UwVzuYbzUBJtXrkp_JL2afeCGKm3wyPMMZbZlzAtH4QsHiPoUIoVEEnmaf2-rnaDYq6ejqSpg=)

8. [s4shops.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHOUy-intNzWdseHIn0vwboUQUoVHfCr9Z_7JrXY3XG44FQ_U_KyhYevkeOfU8cXD_yccP4WSZTkjtHb_a4doOAiRT69Z4KHj1BG6LZxvkKyVZlFJhcyYKeisYyFoG-0Y-Jj18l0teRJxs=)

9. [bocsci.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGI5ygvu-1so50-vXLRBwUATEFP_KdAlDLea9UIcKFRafFsRXhPnY2Yk6kiRcCq7BkBu60vtxKgpTxIxy3aVOwCESI_6sBmPmOQdwhE1BgvK7KrIqDZ6kqNJIyrn8XQyaY1jvj-3kuMlvQqnJnt1ksvLaqkxd5RVyOwDir0wBxtY4lczA==)

10. [broadpharm.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHBTCpwYQNEZsdDSZcEnJj5R1DYQxRvwGFZBC-gGD7UF2tHRNE0nPB3MQrPH8T1dlzpBwryBYDN3csgshUaTnsRU2O4b60_qUXxt9gQl8_NwxOy0Af_r3HRwmNvr-k7onUfo-QUDg==)

11. [researchgate.net](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHXNvbvkq0v7i1x4iDeZiq8hEy7CSx5tfC9WZvjlTtuScjMyk8d_QzFt5Jy_LQSsFRR3fnDC-SgXQFuXiIoIbrnCIwFXEdc3aAbaFFSCJKZQ9ht9ohieG4YCqCgcUAhHDthEjTXR-7xmsbI__U70M8Lo2O3aWv2a8rRnsBoFtJwbEkMcL2p-jmpN8DRP3Lyo00ayCZ445MyoKRpSCvdzHCiv4CW4oI8dC6tJBDrtbNfdjt-nNdnuA9khyFTMDBvTUwUBWYyF20jkykTN47P0EaOWkG6RCuxs1V8pPg14uZj9JIk9FvqCA==)

12. [nih.gov](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGqpk9dyC91uK9fv8RF7i2-L-qhseMtSpqMU9h_mOpGpO69g-DoiW2cr8lueehbiyAZjtW8-rEq9jGjOWLcsZ5r1xD6U1VYN54VGkDH806lqFTqafoHi1ZhEvAOC83DnQ==)

13. [tandfonline.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEGxMZOAoEKHj-UctS8viS99LKCRNIcxBNaOYwepmsVXEjR4FcvgnGiIiyZ9v61xGQev5kEuBg1ngRaGyHJku8MnPO7431XfqD64Sh09s5Glgn3Mt2em5DYaSbzu9BzxerFz041o1sgMXbsLQhG_yfEZ_dnrQa74BU=)

14. [nih.gov](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGqtVyh0HRWDbXlgGFzLp26–8sC1IFhskjeSFp3Ak_0m9EyZeIiiFQhJIjmwQDLz6s_JuKF0eXGrt4_RK0j7DhVKXjSL1LViLknS7xTAx0XTd71T0JXb-UFM8HKWf5exlDrsC1kjE0Vg==)

15. [ku.dk](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGjpeo-gPuLBvGa4ChhOobXYU7hYOid1qtOHiYitzcOkaw_ZI-y4nDOWvNu0Minci3cXCGxwn3YiUJZJVKOmJClHJckckl7TFRmnTj6lKZX65ovXngNBs1aCeasYs9u6yHVz__GA82__fyIlaiCLQGe608Ra9ERpIrCy0ssyUfuBD_hvf_ettZroLCIq1UdvP1eLDlMJKUhywO0EbQ6xmnotHg1riaH1g==)

16. [nih.gov](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQH2lKAcfWLgajwBnHiChfPYp62HgkWiMc3X3Dn1Z1FNcvEviLJGvBImvWamrovvGesOnFOnjzdB6t7nOWj2fL9CDY2w5Y3kUwQtJW1d33Zps5hb0tdnDEYWZNCR8g7KTo8E-Uafsv5E8A==)

17. [mdpi.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEVenHga9r3zEbCPiIiNGoKwlJ03jRS16JYfEFRnOefP-rrdETZB5i0YFSPbjHW0BQM3WR-9u_mMgLFruCNqy7SgI6kSSd2w0NR_BQJnGLBkMVLGO8M3laJQCjzRdZsGg==)

18. [ajprui.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFSQD4dxdJXdnFT24UzgbCV3rlMF8l6xojCwNFoZjVgiJJdTs7HY9ni8Qjr3HPoBhAvTMWq410ngPwq4AcZxT_YZK2QDR8IL0lofhG_LpaXNG_pFpCJ3Y2DjVsqJjr4E-gaWSZTHB2NkvRsBpg0HXOFGkKUtA==)

19. [viamedica.pl](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGOIQP-Nl4nEkOh1O3niJj5dpSTDJjWgApVe-WGoRX7qcc2o9uXTTVATLbNBX0SGmaRQUQzbCyjnM3D0kcr7AvKuIY0XtzJLZeGYzKxI2krTP4AMdZDAPmT5zTiGgkd90-WdQRMsL01hzxZ2w8XOtqTuLreibgKttDLE-64gDR9qKoqfw==)

20. [jci.org](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQE8ZippQqXNMdX3Ub3wXiuRKewJmibjc5UWwEsKtDVCfg51urorfwDKZHUkBNe5PbiwAUKLnyKqFwmhKw87yfVoptqq8HAOZDpNRelCv2G-aLLrGGBClYpcvlOEx3s8)

21. [frontiersin.org](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGnetZNFeJPeqHqhee-m8inLfZiLUuGNm__kGOz0Zewc-M-PFqp-OKyD42pKFwdRRiD_J8gcPcjjcj2abFK7lvPOvcpIwHrrm9b8ZyW1eVyV2fxz4r0CqlvkpgzjuVYiFB4Oj2Pg-4SiLKNEnqcvv1k6jkQF1L2z9l-kFBjCnMQmNziu-jesFyWxI80s2WqmKY=)